Phase IIb Study on the Safety and Efficacy of BM32, a Recombinant Hypoallergenic Vaccine for Immunotherapy of Grass Pollen Allergy

Update Il y a 4 ans
Reference:

Extract


Inclusion criteria

  • Grass pollen allergy ,J30.1 - Allergic rhinitis due to pollen


Links